Ionis Pharmaceuticals (IONS)

Executive Summary

Ionis Pharmaceuticals is a leader in RNA-targeted therapeutics, leveraging its antisense oligonucleotide platform to address serious genetic, cardiometabolic, and neurological diseases. The company has successfully commercialized multiple FDA-approved therapies, generating recurring revenue and validating its technology. Ionis's pipeline is robust, with several late-stage programs including donidalorsen for hereditary angioedema (Phase 3), olezarsen for hypertriglyceridemia (Phase 3), and ION582 for Angelman syndrome (Phase 1/2). The company's strong financial position, diversified portfolio, and history of clinical success underpin its growth trajectory. Key upcoming catalysts include pivotal trial readouts, regulatory submissions, and potential label expansions, which could drive significant value.

Upcoming Catalysts (preview)

• H2 2026Donidalorsen Phase 3 data for hereditary angioedema85% success
• Q1 2027Olezarsen NDA submission for hypertriglyceridemia70% success
• Q4 2026ION582 interim Phase 1/2 data for Angelman syndrome60% success